PharmAlert.net

PharmAlert Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

The FDA ( U.S. Food and Drug Administration ) has warned that Ibrance ( Palbociclib ), Kisqali ( Ribociclib ), and Verzenio ( Abemaciclib ) used to treat some patients with advanced breast cancers may ...


New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder, kidney and lung. But the treatments, designed to unle ...


The Food and Drug Administration ( FDA ) is alerting health care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of Keytruda ( Pembroliz ...


Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported in the postmarketing setting, some requiring hospitalization. These reactions have occurred during or ...


The FDA ( Food and Drug Administration ) is warning that the liver disease medicine Ocaliva ( Obeticholic acid ) has been incorrectly dosed daily instead of weekly in patients with moderate to severe ...


The FDA ( Food and Drug Administration ) is advising caution before prescribing the antibiotic Clarithromycin ( Biaxin ) to patients with heart disease because of a potential increased risk of heart p ...


Kymriah ( Tisagenlecleucel ), a cell-based gene therapy, is approved in the United States for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia ( ALL ) ...


FDA ( Food and Drug Administration ) is warning that Viberzi ( Eluxadoline; in Europe: Truberzi ), a medicine used to treat irritable bowel syndrome with diarrhea ( IBS-D ), should not be used in pati ...


On 28 April 2016 EMA ( European Medicines Agency ) completed a review of the known risk of pneumonia ( lung infection ) in patients who take inhaled corticosteroid medicines to treat chronic obstructi ...


As a result of an updated review, the FDA ( U.S. Food and Drug Administration ) has concluded that use of the type 2 diabetes medicine Pioglitazone ( Actos, Actoplus Met, Actoplus Met XR, Duetact, Ose ...


The FDA ( Food and Drug Administration ) has warned consumers that homeopathic teething tablets and gels may pose a risk to infants and children. The FDA has recommended that consumers stop using th ...


The FDA ( Food and Drug Administration ) has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines Canagliflozin ( Invokana, Invokamet ) and Dapagli ...


The U.S. Food and Drug Administration ( FDA ) has advised that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, ...


The FDA ( Food and Drug Administration ) has warned about several safety issues with the entire class of opioid pain medicines. These safety risks are potentially harmful interactions with numerous ot ...


The FDA ( Food and Drug Administration ) is eliminating the Risk Evaluation and Mitigation Strategy ( REMS ) for Rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avan ...